Reflections on the dynamic ISSCR 2024 workshop on Standards for Human Stem Cell Use in Research including recommendations for growth factor supply chains for raw (ancillary materials) for cell therapy and ATMP manufacture.
Commercial sources of recombinant human GDF15 protein, in particular those purified from mammalian expression, are frequently contaminated with trace amounts of TGFβ and related proteins. These trace contaminants cause misleading experimental results due to the picomolar or even femtomolar EC50s of this family of cytokines. Please be cautious with your source of recombinant GDF15 protein.
Specialist bioactive growth factor protein manufacturer Qkine today announced a new partnership with StemCultures, a life sciences company dedicated to developing innovative reagents that enhance the quality and efficiency of cell growth and differentiation in culture.
The manufacture of cell and gene therapy products and tissue-engineered regenerative medicine products often requires recombinant proteins such as growth factors and cytokines. These are classified as raw or ancillary materials ie. culture media components or reagents that are not intended to be included in the final product.
We've recently fully transitioned to an animal origin-free (AOF) manufacturing process for our recombinant proteins. This shift ensures the highest standards of safety, purity, and sustainability in bioproduction. By eliminating all animal-derived components, including heparin-based purification columns, we’re supporting ethical and cruelty-free biomanufacturing. Learn more about our journey to 100% AOF.
As part of our commitment to constantly improving growth factor quality and availability, we will introduce a modest price increase on January 1st 2024.
Qkine has appointed Thomas Scientific as a new US Distribution Partner, making it easier for stem cell scientists in the US to purchase the entire Qkine product portfolio.
Qkine is pleased to announce a new sales distribution agreement with industry-leading European distributor, CliniSciences.
Qkine collaborates with the Cambridge Stem Cell Institute to facilitate same-day access to key research products for researchers at the Cambridge Biomedical Campus
Qkine is excited to be shortlisted for the Business Weekly Awards 2023 alongside scaling and inspirational companies in the Cambridge cluster.
© 2024 Qkine Ltd. Company number 10470662 registered in England and Wales. All rights reserved
